Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform Avacta Group plc ("Avacta" or "the Group" or "the Company")Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform London, Oct. 17, 2024 – Avacta Group plc (AIM:...

Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer London, Oct. 15, 2024 –...

Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer London, Oct. 15, 2024...

Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act...